Newborn Screening for X-Linked Adrenoleukodystrophy

Area of Science:

• Biochemistry
• Genetics
• Pediatrics

Background:

• X-linked adrenoleukodystrophy (X-ALD) is a rare genetic disorder affecting males, potentially leading to adrenal insufficiency and neurological damage.
• Early diagnosis is critical for timely intervention, particularly for the childhood cerebral form, to improve patient outcomes.
• Hematopoietic cell transplantation is a key therapy for the cerebral form of X-ALD.

Purpose of the Study:

• To describe X-linked adrenoleukodystrophy (X-ALD) and its current therapeutic landscape.
• To detail the historical development and approval process for X-ALD newborn screening.
• To report on the successful implementation and expansion of X-ALD newborn screening programs.

Main Methods:

• Review of the history and development of X-ALD newborn screening tests.
• Analysis of the approval process for inclusion in the Recommended Uniform Screening Panel (RUSP).
• Case study of the implementation of X-ALD newborn screening in New York State and subsequent expansion.

Main Results:

• X-ALD newborn screening was successfully implemented in New York starting December 30, 2013.
• Follow-up guidelines have been established in New York to manage screened infants.
• Early successes in New York, Connecticut, and California indicate a positive trajectory for broader X-ALD newborn screening adoption.

Conclusions:

• Newborn screening for X-ALD is essential for early diagnosis and intervention.
• The successful implementation in New York serves as a model for other states and countries.
• Expansion of X-ALD newborn screening programs is anticipated, with international interest and legislative approvals in several US states.